胰腺癌新辅助化疗后孕酮受体和Ki-67的水平变化研究

Study on changes of progesterone receptor and Ki-67 levels after neoadjuvant chemotherapy in pancreatic cancer

目的探讨和分析胰腺癌患者行新辅助化疗后孕酮受体、Ki-67的水平变化的临床意义。方法选取2009年1月至2013年3月在该院胰腺外科行新辅助化疗治疗的患者72例,分析化疗前后孕酮受体、Ki-67水平与治疗效果之间的关系。结果 72例患者总治疗有效率为86%,且化疗前后孕酮受体及Ki-67的表达水平比较,差异有统计学意义(P<0.05);分析显示化疗前后孕酮受体、Ki-67表达水平的变化与化疗疗效有紧密的相关性(P<0.05)。结论对于行新辅助化疗治疗的胰腺癌患者,可以通过分析孕酮受体、Ki-67表达水平的变化情况来分析其化疗疗效,对临床治疗方法的选择有积极意义。

Objective To explore the clinical significance of changes of progesterone receptor（PR）and Ki-67 levels after neoadjuvant chemotherapy in the patients with pancreatic cancer.Methods 72 patients treated by the neoadjuvant chemotherapy in the pancreatic surgery of our hospital from January 2009 to March 2013 were selected.The relationship between the PR and Ki-67 levels before and after chemotherapy with the treatment effect was anlyzed.Results The total effective rate in 72 cases was 86%,moreover the PR and Ki-67 expressions had statistical differences between before and after chemotherapy;the analysis showed that the PR and Ki-67 expression levels had close relation with the chemotherapeutical efficacy（P〈0.05）.Conclusion For the patients with pancreatic cancer treated by the neoadjuvant chemotherapy,the chemotherapeutic effect can be analyzed by analyzing the change situation of PR and Ki-67 expression levels,which has active significance to the selection of clinical treatment methods.